Cue Biopharma (CUE) Assets (2017 - 2025)
Cue Biopharma (CUE) posted Assets of $42.2 million for Q4 2025, up 33.4% sequentially from $31.6 million in Q3 2025, and up 31.13% YoY from $32.2 million in Q4 2024.
Cue Biopharma (CUE) Assets (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Assets for 9 years, with the latest figure at $42.2 million in Q4 2025.
- Quarterly Assets rose 31.13% year-over-year to $42.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $42.2 million (up 31.13% YoY) and the FY2025 annual result came in at $42.2 million, up 31.13% from the prior year.
- Assets improved to $42.2 million in Q4 2025 per CUE's latest filing, from $31.6 million in the prior quarter.
- Over five years, Assets peaked at $91.3 million in Q4 2022 and troughed at $22.3 million in Q1 2025.
- A 5-year average of $64.0 million and a median of $71.0 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2021 and 2025: Assets jumped 46.29% in 2021, then tumbled 58.75% in 2025.
- Over 5 years, Assets stood at $83.4 million in 2021, then climbed by 9.45% to $91.3 million in 2022, then tumbled by 32.59% to $61.5 million in 2023, then plunged by 47.68% to $32.2 million in 2024, then surged by 31.13% to $42.2 million in 2025.
- According to Business Quant data, Assets over the past three periods registered $42.2 million, $31.6 million, and $40.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 30.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42.21 Mn |
| Sep 30, 2025 | 31.64 Mn |
| Jun 30, 2025 | 40.71 Mn |
| Mar 31, 2025 | 22.25 Mn |
| Dec 31, 2024 | 32.19 Mn |
| Sep 30, 2024 | 44.81 Mn |
| Jun 30, 2024 | 42.33 Mn |
| Mar 31, 2024 | 53.95 Mn |
| Dec 31, 2023 | 61.53 Mn |
| Sep 30, 2023 | 68.89 Mn |
| Jun 30, 2023 | 73.16 Mn |
| Mar 31, 2023 | 81.68 Mn |
| Dec 31, 2022 | 91.28 Mn |
| Sep 30, 2022 | 76.30 Mn |
| Jun 30, 2022 | 84.75 Mn |
| Mar 31, 2022 | 90.70 Mn |
| Dec 31, 2021 | 83.40 Mn |
| Sep 30, 2021 | 78.88 Mn |
| Jun 30, 2021 | 89.67 Mn |
| Mar 31, 2021 | 88.72 Mn |